Tag: Il 23 inhibitor

According to the National Psoriasis Foundation, many biologics are available to treat inflammatory conditions like psoriasis and psoriatic arthritis, including Skyrizi. For various reasons, patients may need to find a substitute for SKYRIZI, and a wide array of alternative medications and therapeutic strategies exist.

Over 8 million Americans live with psoriasis, a chronic autoimmune condition [1.8.1]. When deciding on a treatment, many patients ask: **Which is better, Otezla or Tremfya?** This article explores the key differences to help inform that decision.

According to clinical studies, up to 45% of patients with moderate to severe Crohn's disease achieved remission after 12 weeks of induction therapy with risankizumab, the active ingredient in SKYRIZI. This potent biologic medication is designed to specifically target an inflammatory protein to manage the disease and provide symptom relief.